血友病治療の世界市場

血友病治療の世界市場は2030年までに米国で138億米ドルに達する見込み

2024年に110億米ドルと推定される血友病治療の世界市場は、2030年には138億米ドルに達し、分析期間2024-2030年のCAGRは3.8%で成長すると予測されます。本レポートで分析したセグメントの1つである遺伝子組換え凝固因子濃縮物治療は、CAGR 3.0%を記録し、分析期間終了までに68億米ドルに達すると予測されます。血漿由来凝固因子濃縮治療セグメントの成長率は、分析期間中CAGR 5.1%と推定されます。

米国市場は30億米ドル、中国はCAGR6.9%で成長すると予測

米国の血友病治療市場は2024年に30億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに28億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と2.9%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の「血友病治療」市場- 主要動向と促進要因のまとめ

血友病治療が世界的に重要な変貌を遂げつつあるのはなぜか？

血友病は、凝固因子の欠乏を特徴とする稀な遺伝性出血性疾患であり、従来は症状を管理し、生命を脅かす出血を予防するために、定期的な因子補充療法の注入に頼ってきました。しかし、世界の治療パラダイムは、消極的治療から積極的かつ長期にわたる介入へと移行しつつあります。疾患に対する認識の高まり、新生児スクリーニングによる診断の向上、専門医療センターへのアクセスの増加により、治療対象患者数が拡大しています。血友病AとBは依然として最も有病率の高い疾患であり、その臨床管理は技術の進歩やQOL、アドヒアランス、長期予後の改善を目的とした画期的な治療法の導入により急速に進化しています。

血友病管理における標準治療はどのような技術革新によって進歩しているのか？

特に半減期が延長された濃縮因子製剤や、投与回数を大幅に減らし皮下投与が可能なモノクローナル抗体などの非因子療法です。遺伝子治療は、血液凝固因子の産生を回復させることを目的とした1回限りの投与により、血友病の根本的な原因をターゲットとする画期的な選択肢として台頭してきています。これらの治療法が承認されたことで、患者と医療提供者双方の長期的ケアへの取り組み方が再構築されつつあります。さらに、デジタルプラットフォームやウェアラブル技術が、出血エピソードのモニタリング、予防投与スケジュールの管理、治療アドヒアランスの追跡に使用されるようになり、それによって治療の旅がパーソナライズされ、実際の治療成績が向上しています。

需要はどこに集中し、どのような利害関係者が進歩を推進しているのか？

北米と西欧は、確立された償還制度、研究インフラ、高い診断率により、血友病治療の最大かつ最も成熟した市場です。特に米国では、血友病治療センターや専門薬局ネットワークを通じて、次世代治療が広く浸透しています。アジア太平洋とラテンアメリカは、特にヘルスケアシステムが希少疾患管理プログラムを強化し、高額治療の適用範囲を拡大していることから、急速に成長しています。非営利団体、患者支援団体、国際保健連合は、特に血漿由来療法が依然として主流である低所得国において、治療アクセスに不可欠な役割を果たしています。官民パートナーシップに支えられたバイオ製薬会社は、救命治療へのアクセスを民主化するための世界の取り組みを加速させています。

世界の血友病治療市場の台頭の原動力は？

血友病治療市場の成長は、世界の診断率の上昇、予防的療法の使用拡大、長時間作用型および非因子療法の採用増加、遺伝子治療プラットフォームの開発進行など、いくつかの要因によってもたらされています。先進的な製造技術によって遺伝子組換え療法のよりスケーラブルな生産が可能になり、皮下および徐放性製剤の革新によってアドヒアランスや静脈アクセスに関する過去の課題に対処しつつあります。さらに、バイオテクノロジー企業と各国のヘルスケアシステムとの戦略的提携により、新興地域における治療薬の供給が改善されつつあります。希少疾病用医薬品の指定や割高な価格設定に対する規制の後押しや、ケアコーディネーションとモニタリングを強化するデジタルヘルスソリューションの登場も、市場成長の主な要因となっています。

セグメント

製品タイプ（遺伝子組換え凝固因子濃縮製剤、血漿由来凝固因子濃縮製剤、デスモプレシン、抗線溶薬）、治療法（オンデマンド、予防）、治療法（補充療法、ITI療法、遺伝子治療）

調査対象企業の例（注目の47社）

• Alnylam Pharmaceuticals Inc.
• Amgen Inc.
• Aptevo Therapeutics Inc.
• AryoGen Pharmed
• Baxter International Inc.
• Bayer AG
• BioMarin Pharmaceutical Inc.
• Biogen Inc.
• Bio Products Laboratory Ltd.
• Chugai Pharmaceutical Co., Ltd.
• CSL Behring
• Dimension Therapeutics
• Ferring Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• GC Pharma
• Grifols, S.A.
• Hemgenix
• Kedrion Biopharma
• Medexus Pharmaceuticals Inc.
• Novartis AG
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Sangamo Therapeutics, Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Hemophilia Treatment Market to Reach US$13.8 Billion by 2030

The global market for Hemophilia Treatment estimated at US$11.0 Billion in the year 2024, is expected to reach US$13.8 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Recombinant Coagulation Factor Concentrate Treatment, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$6.8 Billion by the end of the analysis period. Growth in the Plasma Derived Coagulation Factor Concentrate Treatment segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 6.9% CAGR

The Hemophilia Treatment market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global "Hemophilia Treatment" Market - Key Trends & Drivers Summarized

Why Is Hemophilia Treatment Undergoing a Critical Transformation Worldwide?

Hemophilia, a rare genetic bleeding disorder characterized by the deficiency of clotting factors, has traditionally relied on regular infusions of factor replacement therapies to manage symptoms and prevent life-threatening bleeds. However, the global treatment paradigm is shifting from reactive care to proactive and long-acting interventions. Rising disease awareness, better diagnosis through newborn screening, and growing access to specialized care centers are expanding the treated patient population. Hemophilia A and B remain the most prevalent forms, and their clinical management is evolving rapidly due to technological advancements and the introduction of breakthrough therapies aimed at improving quality of life, adherence, and long-term outcomes.

What Innovations Are Advancing the Standard of Care in Hemophilia Management?

The hemophilia treatment landscape has been revolutionized by a new wave of products, particularly extended half-life factor concentrates and non-factor therapies such as monoclonal antibodies that significantly reduce dosing frequency and offer subcutaneous delivery. Gene therapy is emerging as a transformative option, targeting the root cause of hemophilia through one-time administration intended to restore clotting factor production. The approval of these therapies is reshaping the way both patients and providers approach long-term care. Additionally, digital platforms and wearable tech are now being used to monitor bleeding episodes, manage prophylaxis schedules, and track treatment adherence, thereby personalizing the therapeutic journey and enhancing real-world outcomes.

Where Is Demand Concentrated and What Stakeholders Are Driving Progress?

North America and Western Europe are the largest and most mature markets for hemophilia treatment, thanks to well-established reimbursement systems, research infrastructure, and high diagnosis rates. The United States, in particular, has seen widespread uptake of next-generation therapies through hemophilia treatment centers and specialty pharmacy networks. Asia-Pacific and Latin America are growing rapidly, especially as healthcare systems strengthen their rare disease management programs and expand coverage for high-cost therapies. Nonprofit organizations, patient advocacy groups, and international health alliances play an essential role in treatment access, especially in low-income countries where plasma-derived therapies still dominate. Biopharmaceutical companies, supported by public-private partnerships, are accelerating global efforts to democratize access to life-saving treatments.

What’s Fueling the Rise of the Hemophilia Treatment Market Globally?

The growth in the hemophilia treatment market is driven by several factors, including increasing global diagnosis rates, expanded use of prophylactic therapies, rising adoption of long-acting and non-factor therapies, and ongoing development of gene therapy platforms. Advanced manufacturing technologies are enabling more scalable production of recombinant therapies, while innovations in subcutaneous and extended-release formulations are addressing historical challenges with adherence and venous access. Furthermore, strategic collaborations between biotech firms and national healthcare systems are improving therapy availability in emerging regions. The regulatory push for orphan drug designations and premium pricing structures, along with the emergence of digital health solutions that enhance care coordination and monitoring, are also key contributors to market growth.

SCOPE OF STUDY:

The report analyzes the Hemophilia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment, Antifibrinolytics Agents Treatment); Type (Hemophilia A Type, Hemophilia B Type, Hemophilia C Type); Treatment (On-Demand Treatment, Prophylaxis Treatment); Therapy (Replacement Therapy, ITI Therapy, Gene Therapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Alnylam Pharmaceuticals Inc.
• Amgen Inc.
• Aptevo Therapeutics Inc.
• AryoGen Pharmed
• Baxter International Inc.
• Bayer AG
• BioMarin Pharmaceutical Inc.
• Biogen Inc.
• Bio Products Laboratory Ltd.
• Chugai Pharmaceutical Co., Ltd.
• CSL Behring
• Dimension Therapeutics
• Ferring Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• GC Pharma
• Grifols, S.A.
• Hemgenix
• Kedrion Biopharma
• Medexus Pharmaceuticals Inc.
• Novartis AG
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Sangamo Therapeutics, Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Hemophilia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Diagnosis and Screening Rates for Hemophilia A and B Drive Treatment Uptake Worldwide
  • Innovation in Long-Acting Clotting Factor Therapies Strengthens Business Case for Prophylactic Treatment
  • Emergence of Gene Therapy and Non-Factor Products Throws Spotlight on Curative Hemophilia Solutions
  • Government and NGO-Led Access Programs Expand Treatment Coverage in Low- and Middle-Income Countries
  • Increasing Availability of Recombinant Factor Concentrates Reduces Dependency on Plasma-Derived Products
  • R&D in Bispecific Antibodies and RNAi Therapies Accelerates New Market Entrants
  • Regulatory Approvals of First-in-Class Therapies Propel Competitive Differentiation
  • Improved Patient Education and Home Infusion Training Support Prophylaxis Adoption
  • Growth in Hemophilia Management Apps and Remote Monitoring Enhances Treatment Adherence
  • Collaborations Between Pharma and Advocacy Groups Sustain Momentum in Rare Disease Drug Development
  • Advancements in Extended Half-Life Products Expand Dosing Flexibility and Patient Convenience
  • Commercialization of Gene Therapies by Global Pharma Giants Opens High-Value Revenue Streams
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Hemophilia Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Hemophilia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Hemophilia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Hemophilia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Recombinant Coagulation Factor Concentrate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Recombinant Coagulation Factor Concentrate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Recombinant Coagulation Factor Concentrate Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Plasma Derived Coagulation Factor Concentrate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Plasma Derived Coagulation Factor Concentrate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Plasma Derived Coagulation Factor Concentrate Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Desmopressin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Desmopressin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Desmopressin Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antifibrinolytics Agents Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antifibrinolytics Agents Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Antifibrinolytics Agents Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for ITI Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for ITI Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for ITI Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hemophilia A Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hemophilia A Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hemophilia A Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hemophilia B Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hemophilia B Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Hemophilia B Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Hemophilia C Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Hemophilia C Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Hemophilia C Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for On-Demand Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for On-Demand Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for On-Demand Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Prophylaxis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Prophylaxis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Prophylaxis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• JAPAN
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• CHINA
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: China 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: China 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: China 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: China 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• EUROPE
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Hemophilia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Hemophilia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• FRANCE
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: France 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: France 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: France 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: France 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• GERMANY
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Germany 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Germany 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Germany 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Italy 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Italy 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Italy 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: UK 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: UK 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: UK 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Spain 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Spain 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Spain 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Russia 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Russia 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Russia 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Hemophilia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Australia 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Australia 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Australia 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• INDIA
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: India 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: India 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: India 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: India 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: South Korea 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: South Korea 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: South Korea 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Hemophilia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Latin America 16-Year Perspective for Hemophilia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Latin America 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Latin America 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Argentina 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Argentina 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Argentina 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Brazil 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Brazil 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Brazil 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Mexico 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Mexico 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Mexico 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Hemophilia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Middle East 16-Year Perspective for Hemophilia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Middle East 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Middle East 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Iran 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Iran 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Iran 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Israel 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Israel 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Israel 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: UAE 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: UAE 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: UAE 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030
• AFRICA
  • Hemophilia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Hemophilia Treatment by Product - Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Africa 16-Year Perspective for Hemophilia Treatment by Product - Percentage Breakdown of Value Sales for Recombinant Coagulation Factor Concentrate Treatment, Plasma Derived Coagulation Factor Concentrate Treatment, Desmopressin Treatment and Antifibrinolytics Agents Treatment for the Years 2014, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Hemophilia Treatment by Therapy - Replacement Therapy, ITI Therapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Africa 16-Year Perspective for Hemophilia Treatment by Therapy - Percentage Breakdown of Value Sales for Replacement Therapy, ITI Therapy and Gene Therapy for the Years 2014, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Hemophilia Treatment by Type - Hemophilia A Type, Hemophilia B Type and Hemophilia C Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Africa 16-Year Perspective for Hemophilia Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A Type, Hemophilia B Type and Hemophilia C Type for the Years 2014, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Hemophilia Treatment by Treatment - On-Demand Treatment and Prophylaxis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Hemophilia Treatment by Treatment - Percentage Breakdown of Value Sales for On-Demand Treatment and Prophylaxis Treatment for the Years 2014, 2025 & 2030

IV. COMPETITION